CANF — Can-Fite BioPharma Ltd.

—
NYSE · Health Care · Pharmaceuticals · CIK 1536196 ·
Last close
$1.53
Market Cap
$3.28M
52W High
$12.40
52W Low
$1.42
ADV30
58,943
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 8,055,000 2,985,000 3,200,000
Dec 2025 — — — — 9,514,000 5,528,000 3,922,000
Jun 2025 — — — — 7,720,000 6,454,000 3,536,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-180,790,000
Inventory
—
Receivables
—
ST Investments
$4,058,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$405,000
EBITDA
$-9,730,000
Free Cash Flow
$-5,579,500
Enterprise Value
$-2,001,866
Total Cash
$7,043,000
Total Debt
$49,000
Shares Out
2,142,547
Trailing EPS
$-4.65
Book Value
$2.27
ROE
-211.4%
ROA
-77.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 405,000 -9,950,000 -9,828,000 9,514,000 3,922,000 5,592,000 -8,949,000
Dec 2024 674,000 -8,130,000 -7,880,000 9,120,000 3,680,000 5,436,000 -7,637,000
Dec 2023 743,000 -8,195,000 -7,634,000 9,990,000 3,746,000 6,243,000 -8,440,000
Dec 2022 810,000 -10,096,000 -10,173,000 9,280,000 4,811,000 4,472,000 -10,801,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.27

Peers — same industry

TickerNameMarket CapLastDaily %
CTTH CTT PHARMACEUTICAL HOLDINGS, INC. $3.28M $0.06 —
PMHS Polomar Health Services, Inc. $3.55M $0.13 —
TRAW Traws Pharma, Inc. $3.59M $0.23 —
GRI GRI Bio, Inc. $2.95M $1.35 —
APUS Apimeds Pharmaceuticals US, Inc. $2.94M $1.95 —

News headlines (Yahoo Finance, 1h cache)

Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
2026-11-18 12:00 · Yahoo
Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal
2026-11-12 12:00 · Yahoo
Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
2026-11-09 12:00 · Yahoo
Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
2026-11-06 12:23 · Yahoo
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
2026-11-02 12:00 · Yahoo
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
2026-10-26 11:00 · Yahoo
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
2026-09-09 11:00 · Yahoo
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
2026-09-08 12:20 · Yahoo
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
2026-09-02 13:02 · Yahoo
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
2026-09-02 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.